Prescription Pattern and Awareness of Disease and Treatment in Patients of Parkinson’s Disease

Abstract

More than one APA is commonly prescribed in PD patients. Awareness of disease and treatment of PD is poor among the patients.

Patterns and Determinants of Prescribing for Parkinson’s Disease: A Systematic Literature Review

“…In one study that was conducted in Singapore, the year of the study was not possible to establish [70]. Study settings in prescribing pattern studies varied and included a community setting only ( n = 20) [42–44, 46, 47, 55, 57, 59, 62, 63, 65–71, 73, 75, 84], inpatient and community settings ( n = 9) [45, 50, 54, 56, 58, 60, 61, 72, 74], inpatient setting only ( n = 2) [41, 51], community and care home settings ( n = 2) [48, 53], inpatient, community, and care home settings ( n = 1) [64], and finally, care home setting only ( n = 1) [83]. The general characteristics of the drug prescribing studies that were reviewed are summarised in Table 1.…”

“…The quality assessment of the selected studies using the Joanna Briggs Institute Critical Appraisal Tool is illustrated in Part 6 of Supplementary Materials. Out of the prescribing pattern and determinants studies ( n = 43), two studies were given a quality score of 9 out of 10 (9/10) [45, 49], four studies were given 8/10 [46, 54, 63, 70], seven studies were given 7/10 [51, 56, 68, 73], six studies were given 6/10 [48, 52, 66, 69, 71, 75], eleven studies were given 5/10 [50, 55, 57, 60, 61, 64, 65, 72], ten studies were given 4/10 [42–44, 47, 62, 67, 74], three studies were given 3/10 [41, 53, 58], and finally, one study was given 2/10 [59].…”

“…All of the studies except five [44, 48, 50, 56, 63] calculated the prescription rate of L-dopa. Out of the studies that calculated L-dopa prescription rates, four calculated the prescription rates of L-dopa-carbidopa and L-dopa-carbidopa-entacapone combinations separately [43, 58, 62, 84]; seven studies calculated the prescription rates of both L-dopa-carbidopa and L-dopa-carbidopa-entacapone combinations altogether without distinction [45, 47, 51, 57, 60, 64, 65], and the rest of the studies calculated only L-dopa-carbidopa prescription rates [42, 46, 53–55, 59, 61, 66–75, 83]. None of the studies that used hospital data mentioned if LCIG prescribing rate was calculated except for one Norwegian study [41].…”

“…L-dopa prescription rates were the highest (ranging from 46.50% to 100%) compared to other PD medications in several cross-sectional studies in Italy [73, 75], Japan [74], Spain [71], Singapore [70], USA [45, 64, 69], Sweden and Norway [84], South Africa [57], and India [42, 43, 55]. The lowest L-dopa prescription rates were 21% in 2005 and 2008, found in a Japanese study that used the National Japanese Database to examine the effect of pergolide withdrawal from the USA market on PD medication prescribing patterns in Japan by applying a time interrupted series model [61].…”

“…All bar five studies calculated the prescription rates of DAs (ergot, non-ergot, or both) [44, 50, 56, 63, 75]. Studies that calculated prescribing patterns of DAs can be classified under studies that calculated both ergot and non-ergot DAs prescription rates [43, 51, 53, 54, 58, 61, 62, 66, 67, 71, 73]; DAs prescription rates in general without specifying what type of DAs [42, 45–47, 59, 60, 64, 65, 68, 69, 72, 83, 84]; ergot DAs only [70, 74]; or, non-ergot DAs only [48, 55, 57]. Only four studies examined apomorphine prescribing but without specifying its pharmaceutical formulation forms (subcutaneous injection vs subcutaneous infusion) [53, 62, 67, 73].…”